First collaborative definition of patient centricity

AstraZenecaAstraZeneca announced that BMJ Innovations has published the first collaborative definition of patient centricity for the pharmaceutical industry. The definition was co-developed with patients and caregivers using research led by AstraZeneca and patient community advocates to ensure a deep understanding of patient needs and values. Ten associated patient-centric principles were also identified and published in BMJ Innovations to provide the pharmaceutical industry with a consistent reference point to sustain meaningful and mutually beneficial engagement with patients. Wider testing of these outputs among US and European patient communities confirmed their validity.

The research published in BMJ defines patient centricity as: "Putting the patient first in an open and sustained engagement of the patient to respectfully and compassionately achieve the best experience and outcome for that person and their family." This definition encompassed five clear points of importance to patients that were identified and validated through the research: (1) inclusiveness; (2) sharing goals that are patient and family centred; (3) empowering patients to take control of their own health; (4) working in a way that shows respect, compassion and openness; and (5) working in partnership.

Patricia Furlong, President and CEO of Parent Project Muscular Dystrophy and a co-author of the research, said: "This is a landmark project for the pharmaceutical industry. As patients and caregivers, we are eager to see industry engaging with patients in a meaningful way to deliver what we actually want. This definition and set of guiding principles creates a clear signpost for industry by establishing a goal for how to meaningfully put patients at the centre of work by involving them in decision-making in a way that truly benefits them."

Guy Yeoman, Vice President, Patient Centricity at AstraZeneca, said: "We asked patients what they wanted our industry to focus on, and we heard very clearly that they wanted us to stop concentrating solely on what we deliver, and think about how we deliver it. If we get the 'how' right, then the 'what' will be so much more meaningful and impactful for patients. For the first time, we believe we have a definitive direction for how patient engagement should be conducted in the way we, as an industry, research and develop our medicines."

AstraZeneca's research included extensive engagement with patients, including interviews with individual patients and patient organisations, and interaction with patients through an online forum and patient advisory boards. Healthcare providers and payers also provided input on patient needs. Following the data collection, researchers conducted two patient workshops designed to develop a definition of patient centricity and identify relevant principles for pharmaceutical companies that are most important to patients. Developed by a total of 22 patients and caregivers across a wide variety of conditions from North America and Europe, the principles were also validated via 470 and 703 patients in the PatientsLikeMe and Carenity online networks, respectively.

Yeoman G, Furlong P, Seres M, et al.
Defining patient centricity with patients for patients and caregivers: a collaborative endeavor.
BMJ Innovations Published Online First: 24 March 2017. doi: 10.1136/bmjinnov-2016-000157.

About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Novartis' Ultibro® Breezhaler® significantly impro…

Novartis today announced positive results from the FLASH** study examining the safety and efficacy of directly switching chronic obstructive pulmonary disease (COPD) pati...

New Novartis Entresto® real world evidence data sh…

Novartis has announced new results from a real-world database study of patients in Germany prescribed Entresto® (sacubitril/valsartan) for heart failure with reduced ejec...

FDA approves pill with sensor that digitally track…

The U.S. Food and Drug Administration has approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) ...

Scientists find natural mimetics of anti-cancer …

Researchers from the Biogerontology Research Foundation, Insilico Medicine, Life Extension and other institutions announce the publication of a landmark study in the jour...

Novartis, ASCP and ACS join forces to fight cancer…

Novartis, the American Society for Clinical Pathology (ASCP) and the American Cancer Society (ACS) will work together to devise a common approach to improve access to ca...

World's smallest tape recorder is built from micro…

Through a few clever molecular hacks, researchers at Columbia University Medical Center have converted a natural bacterial immune system into a microscopic data recorder...

Using social media big data to combat prescription…

Researchers at Dartmouth, Stanford University, and IBM Research, conducted a critical review of existing literature to determine whether social media big data can be used...

Discovery of a promising medication for amyotrophi…

Researchers from the University of Montréal Hospital Research Centre (CRCHUM) and the Cumming School of Medicine (CSM) at the University of Calgary have discovered a medi...

Sclerosis medicine can fight multi-resistant bacte…

Encountering bacteria with innocent names such as Pseudomonas aeruginosa and Enterobacteriaceae can lead to hospitalisation and - in a worst-case scenario - can also be l...

Mushrooms are full of antioxidants that may have a…

Mushrooms may contain unusually high amounts of two antioxidants that some scientists suggest could help fight aging and bolster health, according to a team of Penn State...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]